A global leader in real world health intelligence, Analytica Laser is powered by a renowned scientific team of 140+ senior experts across eight offices. Our consulting, research and data services are employed by the leading biopharma and public health innovators in over 20 countries. Every day, our work directly benefits millions of patients in advancing access to new therapies that are safer, more convenient and more affordable.

2. As a global research consultancy,
we are committed to providing the
highest level of scientific evidence
on the value of medicines and
health technologies
Analytica Laser studies and services currently
reach more than 20 countries
Our senior team unites more than 110 specialists
and consultants including 40 PhD/MD/PharmD
and 50 MSc/BSc
MAIN OFFICES
NEW YORK
MONTRÉAL
LONDON
PARIS
MADRID
MILAN
KRAKOW
BASEL/LÖRRACH

3. WELL-POSITIONED TO
PROVIDE STRATEGIC
CONSULTING AND
SCIENTIFIC RESEARCH
SERVICES TO HEALTHCARE
INNOVATORS AROUND
THE WORLD

4. GLOBAL SERVICE LINES
REAL WORLD
DATA SOLUTIONS
DECISION ANALYTICS
+ MODELING
VALUE + ACCESS
CONSULTING
Burden of illness+
Outcomes research+
Quality of life+
Drug utilization+
Resource use+
Continuous benefit/risk+
PAES / PASS+
PGRx+ proprietary datasets
Electronic health data+
US healthcare databases+
Surveys+
+ Predictive modeling
+ Performance software
+ Bridging studies
+ Bayesian statistics
+ MTC / NMA
+ Disease modeling
+ Economic modeling
+ Enriched RCTs
+ Clinical trial analytics
Market access consulting+
Health economics+
Outcomes+ -based
agreements
Reimbursement+
submissions
Core HTA submissions+
Systematic reviews+
Global value dossiers+
Investment strategy+
MCDA+

5. REAL WORLD
DATA SOLUTIONS
Our real world data group offers solutions for every need, from
niche needs identification, justifying access, differentiating
value, quantifying an opportunity to demonstrating benefit/risk.
Analytica Laser’s proprietary PGRx Real World Datasets are a
unique source of real world data with a variety of applications.
Powered by the strongest epidemiology team in the industry,
we also offer multiple solutions for advanced observational
studies in risk and effectiveness research, as well as custom
outcomes research programs.

6. Our observational study experts, health economists
and PRO specialists join forces with operational
teams across Europe and North America to design
and conduct HEOR studies as well as Advanced
Pharmacoepidemiology research. Our work is
regularly published in the leading journals:
+ The Lancet
+ Value in Health
+ Amer J Epidemiology
+ Diabetes Care
+ Blood
+ Int J Medicine
+ Pharmacoepidemiology &
Drug Safety
+ Heart
+ Arthritis & Rheumatology
OUTCOMESRESEARCH&
PHARMACOEPIDEMIOLOGY

7. REAL WORLD DATA SOLUTIONS ACROSS
THE EVIDENCE CONTINUUM
Unmet need+
Treatment patterns+
Burden of illness+
Market sizing+
Cost minimization+
Cost offsets+
Cost effectiveness and+
budget impact analysis
+ Drug utilization studies
+ Relative effectiveness
+ Outcomes performance
+ PAES
Benefit/risk assessment+
Risk management+
Signal detection+
PASS+
+ Electronic health
records
+ Administrative
medical records
+ Chart reviews
+ Ad hoc surveys
+ Observational
studies
QUANTIFY
OPPORTUNITY
JUSTIFY ACCESS
MEASURE
PERFORMANCE
ENSURE SAFETY

8. ELECTRONIC DATABASES STUDIES
+ UK
+ France
+ Denmark
+ Germany
+ Italy
+ Spain
+ Israel
+ USA
+ Sweden
PGRx REAL WORLD DATASETS
MEDICAL INFORMATION + PATIENT VOICE
30+ epidemiologists, statisticians and data managers provide analysis and study
design services leveraging electronic healthcare databases available for various key
markets.
Available for license, Analytica Laser’s proprietary PGRx Real World Datasets offer a
unique opportunity for obtaining extremely high-quality data in real-time, combining
both medical information extracted from medical records and linkage to patients
questionnaires. Datasets are currently available for 12 therapeutic areas and more
than 20 disorders.

9. WHEN THE QUESTION IS…
…the quality of PGRx data makes a real difference
understanding patient needs…
PGRx data showed that the quality of life of patients with acute coronary syndrome varies greatly according to
risk factors and forms of the disease1, impacting drastically the burden of illness and the cost-effectiveness
assessment of the different interventions.
1Value in Health, 2015
ensuring safety…
PGRx data were used in multiple risk management plans. It generalised the methodology used in the famous
“fen-phen” study (IPPHS2) conducted by Lucien Abenhaim, which had uncovered the risk of these drugs and thus
prevented an epidemic of fatal disease in Europe and the US.
2New England J Medicine
expediting access…
With price negotiations at an impasse, PGRx was accepted by payers as offering the necessary confidence in
product value for a conditional pricing arrangement in the prevention of stroke by new anticoagulants. A similar
method was used for confirming the role of statins in the prevention cardiovascular disorders3.
3Int J Cardiology, 2014

10. Our scientific advice enjoys the attention of regulators, payers and HTA
bodies around the world. We are excited that our expertise has been
requested by various recent public-private initiatives
+ Improving methods for post-launch safety monitoring and real-time benefit risk
assessment
+ Member, Work Programme 2: Pharmacoepidemiology study designs framework
+ Leader, Work Programme 6: Methods validation in multiple data sources
+ Innovating RWE methods to inform clinical R&D decision-making, relative
effectiveness evaluation
+ Leader, Work Package 2: Leverage RCTs and Phase IIIb studies to decrease efficacy-to-
effectiveness gap
+ Organizing multi-centre,
independent, post-authorization
studies to strengthen the monitoring of
authorized medicines in Europe
+ Regular participant in ENCePP
Plenary Sessions and Scientific
Conventions
+ Principal investigator of 1 ENCePP-
registered collaborative study
+ Protocol reviewer of 1 ENCePP-
registered collaborative study

11. DECISION ANALYTICS
+ MODELING
Leveraging best-in-class capabilities in modeling, simulation,
mathematics and Bayesian statistics, Analytica Laser employs
advanced analytics frameworks and proprietary software to study
real world outcomes for drug value assessment.
Through the suite of proven methodologies, our team of experts
can leverage information available at any stage of development
and market access process. This informs strategic decisions for
drug evaluation and evidence generation.

12. Gaps in real world evidence have emerged
as a critical challenge across the product
lifecycle. Being able to explore a series of
highly complex scenarios in a timely
manner is more vital than ever
From early stage development to launch,
reimbursement, and outcomes performance
– we help you navigate the most difficult
trade-off decisions
We can draw on a global team of statisticians,
epidemiologists and analysts with expertise in
advanced predictive modeling and simulation

13. ANALYTICS AND MODELING SERVICES ACROSS THE PRODUCT LIFECYCLE
Analytica Laser has contributed to advance the methodological development in MTC and Bayesian meta-analysis
and in large IMI/EU funded research projects on benefit/risk characterization and communication.
PHASE
II
PHASE
III
REGISTRATION ACCESS EXPANSION
R&D
Drug positioning+
Optimal design and+
planning
Pipeline prioritization+
PRE-MARKETING
+ Launch strategy
+ Pragmatic trial design
+ Payer-relevant evidence
and value development
POST MARKETING
Risk sharing strategy+
Performance plan models+
Predicting comparative effectiveness+
Real world cost effectiveness models+

14. The interaction of risk factors with drug
efficacy is not what varies from one
population to another – it is the distribution
of these factors that does. This is why drug
effectiveness may be different from
country to country, or from one healthcare
system to another
PROF. LUCIEN ABENHAIM
Pioneer of Pharmacoepidemiology
Former Executive Board Member, World Health Organization

15. OUR PROVEN FRAMEWORK FOR “BRIDGING TO EFFECTIVENESS”
Coverage+
Medical Practices+
Screening Policies+
Patterns of use, dose,+
treatment duration
Past history of exposure+
Co+ -prescriptions
Adherence+
+ Age, gender, behaviors
+ Co-morbidities
+ Disease stage/severity
+ Other baseline risk factors
and genetics relevant to
disease/drug
HEALTH CARE SYSTEM
EFFICACY
EFFECTIVENESS
The team specializes in bridging efficacy to
effectiveness in terms of modeling:
+ Clinical trial to real-life populations
+ Proxy outcome to actual outcome
+ Country to country
+ One comparator to another
DRUG USE PATIENT POPULATION

16. REAL
WORLD
IMPACT
PATIENTS
EXPOSURE
SYSTEMS
USERS CHARACTERISTICS
Patients demographics, prognosis factors,+
treatment pattern history
USE
+ Prescription patterns,
decision rules to
switch or adjust dose
+ Patients adherence
and patterns of use HEALTHCARE SYSTEM FACTORS
Coverage+
Medical practices policies+
The industry’s first dynamic and
versatile tool dedicated to building
predictive models for effectiveness
We’re using our proprietary
technology HOPE to translate
clinical trial findings and population
health knowledge into expected
real world impact. Based on a
Bayesian dynamic modeling engine,
it allows for consideration of
dynamic exposure and influence
of risk factors in its predictions.

17. DEAL OR NO DEAL?
DECISION ANALYTICS FOR OUTCOMES-BASED CONTRACTING
Across all health systems, payers and reimbursement authorities are urging the adoption of
performance-based contracting. What if you’d be able to identify the sources and quantify the
impact of uncertainty around outcomes-based agreements?
Our proprietary HOPE technology enables us to:
Test highly complex scenarios to optimize your plan design and inform payer negotiations and contracting+
Understand what outcome, comparator and time horizon to select+
Define the best methods to measure performance and opt for the most appropriate payment models+
YOUR REAL WORLD
SETTING
CLINICAL TRIAL
EFFICACY
RELEVANT
DRIVERS OF
EFFECTIVENESS
HOPE
MODEL AND
SIMULATION

18. We are committed to removing the
uncertainties between clinical trial
efficacy and real world effectiveness so
that you can succeed with outcomes
predictions and payer engagements
DECISIONANALYTICS
+MODELING
Our global team draws on more
than a decade of experience
leveraging the industry’s most
advanced modeling frameworks for
performance-based agreements

19. VALUE + ACCESS
CONSULTING
Analytica Laser’s diverse teams provide a full range of strategic
market access services in an integrated model.
Our life sciences and medical device partners rely on our
strategic capabilities in real world evidence, advanced
simulation and unique payer insights.
We have completed hundreds of global value dossiers, helped
to secure approval and maintained coverage and
reimbursement through high-quality evidence of value and
impactful reimbursement submissions across all major markets.

20. Our market access consultants follow a structured
V+A analysis to measure what matters for your
product lifecycle management
Payer Research
Quantitative Pricing Research
HTA Strategy
Lifecycle Decision
Analytics
Health Economics
Real World Data
Generation & Analysis
MARKET
ACCESS

21. OUR COMPREHENSIVE APPROACH
In-depth and structured
review of available evidence
Build your product value
dossier based on what
matters to decision-makers
Align with payers’
evidentiary needs and
uncover evidence gaps
Optimize evidence
generation
Measure quantitatively and
qualitatively real world
benefit/risk
Measure real world value
through MCDA studies that
integrate evidence and
regional insights
Positioning and marketing
strategy
Bring the patient voice –
speak the language of
regulators, HTA organizations
and payers
Develop real-world data on
values and preferences
Gain insight on HCPs and
patient values and
preferences (MCDA driven
panels)
Collect rich insights and data
on regulator, HTAs and
payers (MCDA driven ad-
boards)
EVIDENCE
INTELLIGENCE
PRODUCT
INTELLIGENCE
CONTEXT
INTELLIGENCE

22. COVERING BOTH SCIENTIFIC
AND REAL WORLD PERSPECTIVES
Value Message
Development
Strategic Planning
for Optimal Access
Potential Value
Analysis
Scientific
Engagement
Pricing and Payer
Research
Economic models
for HTA
submission and
Regulatory
support
Profile testing,
positioning and
real-life models
Multi-criteria
Decision Analysis
(MCDA)
Consistency &
Continuity:
comprehensive
lifecycle support
Communications
(manuscripts,
presentations,
workshops,
trainings, mock
negotiation)
Core HTA
Submission
(GVD/Value
Dossier)
Reimbursement
Submissions
throughout the
world

23. ENABLING BREAKTHROUGH
INNOVATION FOR
TOMORROW’S CURES
Analytica Laser partners with early stage Biotech
to strategically optimize their market value in the
context of financing or partnering deals.
+ Full asset valuation
+ Target patient population selection
+ Clinical trial design
+ Competitive landscape
+ Pricing studies
+ Preparation and participation to investor and
partnering meetings
We’re leveraging a unique team of senior industry
executives and entrepreneurs, former HTA decision-
makers, scientists, and seasoned strategy consultants
to offer innovative expert advice.

24. EXECUTIVE LEADERSHIP
Lucien Abenhaim
PhD, MD, MSc
CHAIRMAN
London, UK
Fmr+ . Executive Board Member of the
World Health Organization
Honorary Prof. of Epidemiology, London+
School of Hygiene & Tropical Medicine
Roman Casciano
MSc
EVP & GM,
VALUE + ACCESS
New York, USA
+ Founder of Analytica International
+ 20 years’ experience in value assessment,
HEOR and market access strategy
Billy Amzal
PhD, X-Eng, MSc, MPA
EVP, DECISION ANALYTICS
London, UK & Paris, France
15+ + years’ experience in clinical program
design, modeling and analytics
Established and led model+ -based
development at Novartis
Lamiae Grimaldi
PhD, PharmD, MSc, MPH
EVP, EPIDEMIOLOGY AND
REAL WORLD DATA SOLUTIONS
Paris, France
+ 15+ years’ experience in clinical
pharmacology & pharmacoepidemiology
+ Co-founder of PGRx System

25. EXPERT MANAGEMENT TEAM
Sumeet Bakshi
MBBS, MMS, MBA
London, UK
VP, Real World Evidence Solutions+
17+ + years’ experience, fmr. Pfizer
and J&J
Patrizia Berto
PharmD, MBA
Milan, Italy
+ Sr. Global Consultant and
Managing VP, Italy
+ 30 years’ in biopharma with 20
years’ of HECON/ MA consulting
Matthew Brougham
MSc, DipHeathEcon
Montréal, Canada
Sr. Global Consultant+
Fmr+ . VP, CADTH (Canada) and Fmr. CEO,
PHARMAC (NZ)
20+ + years’ HTA/HEOR experience
Emmanuel Coeytaux
PhD, X-Eng
New York, USA
Managing VP, Strategy Consulting+
15+ + years’ experience, fmr. R&D Strategy
Director at Sanofi and BCG Principal

26. Jessica Jalbert
PhD
New York, USA
+ Director of Pharmacoepidemiology
+ Assistant Prof. of Healthcare Policy and
Research, Weill Cornell Medical College
Jenifer Ehreth
PhD
Paris, France
Sr. Global Consultant+
15+ + years’ experience in biopharma
and devices
+ University Prof. in Health Economics
Hélène Karcher
PhD, X-Eng
Basel, Switzerland
+ VP, Global Head of RW Modeling
+ Fmr. MIT academic and drug developer
(Novartis US/Europe)
Artak Khachatryan
PhD, MD
London, UK
+ Sr. Director, Pharmacoepidemiology
+ 10+ years’ experience as lead
epidemiologist in various international
studies
Hanane Khoury
PhD
Montréal, Canada
Assoc. Director, MCDA expert and Lead+
investigator for the EVIDEM collaboration
10+ + years’ experience in MCDA and
reimbursement dossier development
Marta Martinez
PharmD, MBA
Madrid, Spain
+ Director, Outcomes Research
+ 10+ years’ experience in CROs and industry

27. Dima Samaha
PharmD, MAS
London, UK
Sr. Director, Value & Access+
Fmr+ . Advisor on Innovation and External
Affairs at INESSS, Québec
Ulrich Neumann
MSc, MA, FRSA
New York, USA
Sr. Director, Commercial Development+
Business Consultant, Outcomes+ -based
Contracting
+ 15 years’ experience in marketing
Lee Stern
MSc
New York, USA
+ VP, Business Development
+ 15+ years’ experience in HEOR
Jacek Walczak
MD, Spec
Krakow, Poland
VP, Central and Eastern Europe+
15+ + years’ experience global market
access and systematic reviews
Elvira Müller
PhD, MPH
Lörrach, Germany
Managing VP, Germany+
15+ + years‘ experience in HTA and global
market access

28. WHY ANALYTICA LASER?
SCIENTIFIC
RIGOR
+
POPULATION
HEALTH INSIGHTS
ANALYTICAL
EXCELLENCE
+
DECISIONAL
RELEVANCE
REAL WORLD
KNOWLEDGE
+
STRATEGIC
INTELLIGENCE